


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

PROFIT ALERT

This announcement is made by Kaisa Health Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment on the unaudited consolidated accounts of the Group for the year ended 31 December 2021 and the information currently available to the Board, the Group is expected to record a profit attributable to the owners of the Company in the range of HK\$1 million to HK\$3 million for the year ended 31 December 2021 as compared to the loss attributable to the owners of the Company in the amount of approximately HK\$40 million for the year ended 31 December 2020.

Such profit was primarily attributable to a combination of factors as follows:—

- (i) the Group recorded an increase in income of approximately 14% for the year ended 31 December 2021 as compared with that of the year ended 31 December 2020, due to a recovery of dental prosthetics business and an expansion of healthcare business, which resulted in an increase in gross profit of approximately HK\$7 million;

- (ii) the reversal of expected credit loss on convertible bonds receivable or loan receivable in the amount of approximately HK\$27 million;
- (iii) a gain from the change in financial assets at fair value through profit or loss in the amount of approximately HK\$57 million;
- (iv) increases in administrative expenses and finance costs due to the expansion of healthcare business in the amount of approximately HK\$30 million and HK\$6 million respectively; and
- (v) an increase in income tax expense due to the gain on disposal of financial assets at fair value through profit or loss which incurred approximately HK\$24 million tax expense.

The Company is still in the process of finalising the annual results of the Group for the year ended 31 December 2021. The information contained in this announcement is only based on the unaudited consolidated accounts of the Group for the year ended 31 December 2021 and the information currently available to the Group, which have not been audited or reviewed by the auditors of the Company. Details of the financial results of the Group will be disclosed in the Group's annual results announcement for the year ended 31 December 2021 which will be published in due course pursuant to the requirements of the Listing Rules. Shareholders and potential investors are advised to read the annual results announcement carefully when it is published.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Kaisa Health Group Holdings Limited
Zhang Huagang
Chairman

Hong Kong, 28 March 2022

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Zhang Huagang (Chairman), Mr. Luo Jun (Co-Vice Chairman), Mr. Wu Tianyu (Co-Vice Chairman) and Mr. Kwok Ying Shing, and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Yonglan.